Search Within

Raajit Kumar Rampal

Formats
  1. Meeting Abstract (191)
  2. Journal Article (123)
  3. Review (21)
  4. Research Letter (10)
  5. Book Section (2)
  6. Editorial (2)
  7. Guidelines (1)
  8. Miscellaneous (1)
Groups
  1. Adult Leukemia (351)
  2. Center for Hematologic Malignancies (351)
  3. Department of Medicine (351)
  4. Hematologic Malignancies, Division of (351)
  5. GSK Faculty (135)
  6. Executive Committee, Center for Hematologic Malignancies (131)

More Groups

People
  1. Ross Levine (87)
  2. Omar Abdel-Wahab (64)
  3. Martin Tallman (41)
  4. Eli Diamond (34)
  5. Ahmet Dogan (30)
  6. Minal Patel (29)

More People

Years
  1. 2025 (15)
  2. 2024 (35)
  3. 2023 (42)
  4. 2022 (36)
  5. 2021 (36)
  6. 2020 (26)

More Years

Publications
  1. Blood (148)
  2. Journal of Clinical Oncology (18)
  3. Blood Advances (15)
  4. Clinical Lymphoma, Myeloma and Leukemia (15)
  5. Haematologica (13)
  6. British Journal of Haematology (10)

More Publications

Publishers
  1. American Society of Hematology (164)
  2. Elsevier Inc. (24)
  3. Nature Publishing Group (22)
  4. American Society of Clinical Oncology (18)
  5. Ferrata Storti Foundation (13)
  6. American Association for Cancer Research (12)

More Publishers

Results (351)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies
    Journal Article

    Krystel-Whittemore, M.; Petrova-Drus, K.; Ptashkin, R. N.; Ewalt, M. D.; Yao, J.; Liu, Y.; Zhu, M.; Benhamida, J.; Durham, B.; Kumar, J.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis
    Meeting Abstract

    Rampal, R.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naive myelofibrosis
    Meeting Abstract

    Mascarenhas, J.; Maher, K. R.; Rampal, R.; Bose, P.; Podoltsev, N. A.; Hong, J.; Wang, X.; Kye, S.; Harrison, C.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 2 study evaluating selinexor monotherapy in patients with JAKi-naive myelofibrosis and moderate thrombocytopenia
    Meeting Abstract

    Scandura, J.; Gerds, A. T.; Ritchie, E. K.; Wang, X. L.; Kye, S.; Rampal, R.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib in the United States
    Meeting Abstract

    Marrone, M.; Geller, R.; Oladapo, A.; Suthar, P.; Vasudevan, A.; Vredenburg, M.; Zeng, J.; Rampal, R.; Mascarenhas, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy
    Journal Article

    Friedman, J. S.; Durham, B. H.; Reiner, A. S.; Yabe, M.; Petrova-Drus, K.; Dogan, A.; Pulitzer, M.; Busam, K. J.; Francis, J. H.; Rampal, R. K.; more...
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
    Journal Article

    Patel, A. A.; Yoon, J. J.; Johnston, H.; Davidson, M. B.; Shallis, R. M.; Chen, E. C.; Burkart, M.; Oh, T. S.; Iyer, S. G.; Madarang, E.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Focus on the use of tagraxofusp and clinical considerations
    Review

    Pemmaraju, N.; Madanat, Y. F.; Rizzieri, D.; Fazal, S.; Rampal, R.; Mannis, G.; Wang, E. S.; Foran, J.; Lane, A. A.
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: Final results
    Journal Article

    Yacoub, A.; Borate, U.; Rampal, R. K.; Ali, H.; Wang, E. S.; Gerds, A. T.; Hobbs, G.; Kremyanskaya, M.; Winton, E.; O’Connell, C.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Interferons in the treatment of myeloproliferative neoplasms
    Review

    Vachhani, P.; Mascarenhas, J.; Bose, P.; Hobbs, G.; Yacoub, A.; Palmer, J. M.; Gerds, A. T.; Masarova, L.; Kuykendall, A. T.; Rampal, R. K.; more...
    Therapeutic Advances in Hematology (2024)

    Fulltext@MSK | Save